Tehran University of Medical Sciences

Science Communicator Platform

Faculty Members have conducted research related to the Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial
Ebrahim Esmati
Ebrahim Esmati

Associate Professor of Radiation Oncology

Department Radiotherapy

School of Medicine

Imam Khomeini Hospital Complex,Cancer Institute

Tehran University of Medical Sciences

All Documents
35. Evaluation of Contrast Agent Dose and Diffusion Coefficient Measurement on Vessel Size Index Estimation, Magnetic Resonance Materials in Physics# Biology and Medicine (2019)
44. Radiotherapy for Ewing Sarcoma: A 5 Year Experience From Iran Cancer Institute, International Journal of Radiation Research (2016)
45. Neuroendocrine Carcinoma of the Tongue, Journal of Cancer Research and Therapeutics (2015)